Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor...
Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
About this item
Full title
Author / Creator
Publisher
Singapore: Springer Singapore
Journal title
Language
English
Formats
Publication information
Publisher
Singapore: Springer Singapore
Subjects
More information
Scope and Contents
Contents
Objective
In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognos...
Alternative Titles
Full title
Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8732811
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8732811
Other Identifiers
ISSN
1867-1071
E-ISSN
1867-108X
DOI
10.1007/s11604-021-01174-w
